Kornimate/medical-research-clean huggingface dataset:
sibling and unrelated donor hematopoietic cell transplant in hematologic malignancies

Conditions: Acute Disease; Myelodysplastic Syndromes; Leukemia, Myeloid, Chronic; Myeloproliferative Disorders; Blood and Marrow Transplant (BMT); Myelodysplastic Syndromes (MDS); Leukemia

Summary: the purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (mds) or myeloproliferative disorders (mpd).

to learn whether a new preparative regimen to prepare patients for bone marrow transplantation is useful in patients above 50 years of age and whether it is useful in patients with myelodysplastic syndromes.

Eligibility criteria:
inclusion criteria:1) patients aged 51-60 with acute non-lymphocytic leukemia in first or subsequent remission and acute lymphocytic leukemia in first remission with high risk features which include elevated white blood cell count at presentation, cytogenetic abnormalities, extramedullary leukemia, all in greater than first remission and patients with chronic myelogenous leukemia at any stage who have a histocompatible sibling donor. 2) patients with myelodysplastic syndrome including patients with refractory anemia with excess blasts or refractory anemia with excess blasts in transformation. 3) patients with myeloproliferative disorders which give them poor long-term disease-free survival, such as myeloid metaplasia or myeloid fibrosis. 4) patients with secondary myelodysplasia following cytotoxic chemotherapy. exclusion criteria:- organ dysfunction
ropivacaine continuous wound infusion versus intrathecal morphine for postoperative analgesia after cesarean delivery

Conditions: Obstetric Pain

Summary: cesarean delivery is one of the most common surgical procedures, performed at an increasingly high rate. it is associated with intense postoperative pain that may hamper the rehabilitation process and interfere with patient satisfaction and care provided to the newborn. therefore, control of perioperative pain with multimodal regimens using local anesthetic may be important in short- and long-term convalescence after surgery. opioid-based regimens are the "gold standard" of cesarean delivery analgesia. however, spinal and epidural opioids have a ceiling effect. wound infiltration with local anesthetics has been used widely in the multimodal approach of pain relief. continuous wound infusion with local anesthetic through a multiorifice catheter increases the duration of action and efficacy of local surgical wound infiltration compared with a one-time wound injection of local anesthetic. after cesarean delivery, local anesthetic continuous wound infusion would be associated with better reduction in pain scores when compared to intrathecal morphine . therefore, an assessor and patient blinded, randomized study that aimed to compare the efficacy and side effects of these analgesia techniques was conducted.


Eligibility criteria:
inclusion criteria: * women. * age between 18 and 50 years. * gestational age 37 to 42 weeks. * body mass index ranging from 18.0 to 30.0 kg/m2 * american society of anesthesiology (asa) physical status i or ii * elective cesarean delivery with a pfannenstiel incision * spinal anesthesia. exclusion criteria: * history of chronic opioid use. * allergy to opioids and or local anesthetics. * absolute or relative contraindication to neuraxial anesthesia. * fever or any other sign of infection. * diabetes mellitus under insulin therapy * physical separation of patients from the neonate during the postoperative period.

Keywords: ropivacaine wound infusion analgesia cesarean intrathecal morphine randomized controlled trial
pelvital stress urinary incontinence training device: p-suit

Conditions: Incontinence

Summary: the purpose of this investigation is to compare the clinical benefits of using the pelvital product, in comparison to a sham procedure as a noninvasive treatment for female incontinence

120 subjects with sui will be recruited into a randomized, double-blind, sham-controlled crossover trial. subjects will be allocated in a 1:1 ratio (60 per arm) to either the control arm (pfmt) or the treatment arm (pfmt in conjunction with the pelvital therapy). subjects will conduct their respective therapy five minutes a day over the course of six weeks. at weeks two, four and six, the subjects will conduct bi-weekly check-ups. after six weeks, all patients in the control arm will have the option to cross over into the treatment arm if no improvement in symptoms has been shown.

Eligibility criteria:
inclusion criteria: 1. female gender, 2. ages 18-75, 3. clinical diagnosis of stress urinary incontinence, 4. ability to contract the pelvic floor muscles, 5. able to document incontinence and voiding in a diary, 6. provision of written informed consent form, 7. minimum of 10 grams increase at initial 24-hour pad weight test exclusion criteria: 1. diagnosed mixed or urge urinary incontinence, 2. impaired cognitive function or neurologic conditions 3. physical limitations that impede the patient's ability to participate (e.g., ability to stand), 4. acute infections or hematuria, 5. pregnant or actively trying to conceive, 6. history of pelvic irradiation, 7. concurrent medications with α-adrenergic antagonists or diuretics 8. pelvic organ prolapse stage iii or iv, 9. severe urethral sphincter weakness and/or defect, 10. suspected urethral and/or vesical fistula

Keywords: incontinence
sleeve-gastrectomy efficacy in morbid obese patient with a focus on the role of inflammation

Conditions: Morbid Obesity

Summary: despite the wide range of studies concerning the positive effects of bariatric surgery on metabolic state of morbid obese patient, it is necessary to further investigate the specific role of the "sleeve-gastrectomy" intervention, going not only to research results in terms of safety or efficacy on the treatment of comorbidities, but also aimed to understand whether the improvement of metabolic and cardiovascular parameters is due to total weight loss or rather to visceral fat loss, and how much of this improvement is attributable to changes in inflammatory status. the primary endpoint of the study is to evaluate the effect of sleeve-gastrectomy on metabolic parameters (glyco-lipidic assessment, vitamins), bone-remodelling parameters (vitamin d, parathormone) and cardiovascular parameters (blood pressure, flow-mediated dilation, indexed left ventricular mass, inter-ventricular septum, carotid intima-media thickness) in a large obese population on the basis of total weight loss (twl), variation of visceral fat area (vfa), variation of peri-renal fat thickness and insulin resistance index ("homeostasis model assessment-insulin resistance" - homa). in addition the investigators set themselves the objective of assessing whether the presence of comorbidities (diabetes and hypertension) can influence the effects of the intervention on the above parameters, and whether the levels of the nets and of adipokines such as chemerin in the pre- and post-intervention can correlate with the metabolic-vascular dysfunction, and play a role in its eventual improvement.


Eligibility criteria:
inclusion criteria: - bmi ≥ 40 kg / m2 (or ≥ 35 kg / m2 with at least one comorbidity), aged between 18 and 65 years. exclusion criteria: * renal or hepatic impairment * heart failure (new york heart association - nyha ii-iv) * secondary causes of obesity * major psychiatric disorders
cohort study of patients with her2-negative mbc and brca 1/2 pathogenic mutation

Conditions: Breast Cancer Metastatic

Summary: the purpose of this study is to investigate the prevalence germline pathogenic brca1/2 mutation in a large group of potential candidate of parp inhibitors, among the unselected patients with her2-negative unresectable locally advanced or metastatic breast cancer.

this is a multicenter, prospective, non-interventional study on the prevalence of germline pathogenic brca1/2 mutation (blood) and somatic pathogenic brca1/2 mutation (tissue, optional) in patients with her2-negative unresectable locally advanced or metastatic breast cancer. 1. for the assessment of germline mutational status of brca1 and brca2, (1)collect peripheral blood from each subject. (2) extract dna from the collected blood. (3)from the extracted dna, germline brca1/2 mutational status will be assessed by next generation sequencing(ngs) using ngenebiobrcaaccutest® 2. for the assessment of somatic mutational status of brca1 and brca2, (1)collect ffpe from about 100 subjects. (2) extract dna from the ffpe. (3)from the extracted dna, somatic brca1/2 mutational status will be assessed by next generation sequencing(ngs) using ngenebiobrcaaccutest® 3. collect variables on the patients and compare clinical outcomes (overall survival, invasive disease-free survival, distant disease-free survival, progression free survival) that can be affected by clinicopathologic characteristics and type of treatment.

Eligibility criteria:
inclusion criteria: * age ≥ 20 years old * histologically confirmed, unresectable locally advanced or metastatic breast invasive carcinoma * human epidermal growth factor receptor 2 (her2) negative breast cancer * germline mutational status of brca1 and/or brca2 can be known or unknown * signed written informed consent * the patient is regarded as good candidate for active palliative management at time of enrollment. the patient with terminal cancer which is not appropriate for further endocrine treatment or chemotherapy cannot be enrolled to this study. exclusion criteria: * her2 positive breast cancer * amenable to curative surgery

Keywords: brca
naltrexone for relapse prevention

Conditions: Alcoholism

Summary: this study is to evaluate the safety and effectiveness of an injectable slow releasing preparation of naltrexone to reduce alcohol consumption and risk of relapse in alcohol-dependent subjects. individuals will receive either naltrexone or a placebo injection for a total of three months, with two subsequent followup visits spanning a 6- month period.


Eligibility criteria:
inclusion criteria: * meets criteria for alcohol dependence. * abstinent from alcohol for a period of at least 3 days prior to beginning of study. * able to read english and complete study evaluations. * females who are postmenopausal, have had surgical sterilization, or use reliable means of birth control. exclusion criteria: * meets criteria for dependence on a psychoactive substance other than alcohol and nicotine and/or cannabis. * prior history of opioid dependence. * regular use of psychoactive drugs including anxiolytics and antidepressants. * prior treatment with naltrexone. * current use of disulfiram. * psychotic or otherwise severely psychiatrically disabled (e.g., suicidal, current mania). * significant underlying medical conditions such as hepatic, cerebral, renal, thyroid, or cardiac disease. * abstinent longer than 28 days prior to randomization.
robot-mediated intervention for children with autism spectrum disorders

Conditions: Autism Spectrum Disorder

Summary: this study is being done to examine the impact of an interactive, social robotics program in helping children with autism spectrum disorders (asd) understand emotions and how to better recognize emotions while interacting with others. eligible families will be randomized to either the robot intervention (n=20) or a no intervention (tau; n=20) condition for 8-14 weeks. assessments will occur at pre- and post-intervention as well as weekly for both conditions.


Eligibility criteria:
inclusion criteria: * child participants must be between the ages of 4 years, 0 months and 8 years, 11 months. * children must meet criteria for asd or autism on the autism diagnostic observation schedule (ados-2; lord et al., 2012) plus receive a clinical judgment of pervasive developmental disorder not otherwise specified (pdd-nos) or autism by the study team. * children must possess sufficient expressive language skills to qualify for at least an ados-2 module 2. * caregivers must agree to participate in the study and commit to having their child participating in the intervention to which they are randomized for approximately three months. * caregivers must agree to bring their child in for pre-testing and post-testing. * family must speak english at least 50% in the home. exclusion criteria: * child iq \<70 (per stanford binet short form). * history of head injury, seizure disorder, severe aggression or self-injurious behavior. * vision impairment after correction. * cannot be living in foster care.

Keywords: intervention autism spectrum disorder social skills
study evaluating desvenlafaxine succinate sustained-release (dvs sr) in adult outpatients with pain associated with diabetic peripheral neuropathy

Conditions: Diabetic Neuropathies; Pain

Summary: the purpose of this study is to evaluate the safety and efficacy of dvs sr in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.


Eligibility criteria:
inclusion criteria: * diabetes type 1 or 2 * painful symptoms of diabetic neuropathy in the lower extremities extremities for at least 6 months exclusion criteria: * major depression * uncontrolled diabetes

Keywords: neuropathic pain diabetic peripheral neuropathy
asthmatic subjects could live without short acting beta2 agonists

Conditions: Asthma Chronic

Summary: since 2006 there was a plateau in world wide mortality from asthma. overreliance in short acting beta2 agonists (saba) was associated with increased risk of death from asthma. long acting beta agonists (laba) alone was not permitted as treatment for asthma as it was determined by fda by the "black box". by contrast saba does not have a "black box", despite similar overuse alerts associated with increased risk of death from asthma. the investigators want to know if exist asthmatic subjects that do use another rescue medication; not saba, and to compare their features, asthma control test (act), and lung function in a outpatient facility. first consecutive visits at outpatient pulmonary section of asthmatic subjects were described. asthma control test (act) that was routinely used to assess asthma and spirometry were performed.

during the period from march 10, 2017 to january 16, 2018 the investigators decided to describe the rescue medication in all new asthmatic subjects that came for a first visit to the outpatient pulmonary department. patients aged ≥16 years were entered in the study with a a diagnosis of asthma, based on a history of episodic dyspnea and wheezing, and/or documented bronchodilator reversibility in forced expiratory volume in 1 s (fev1) of 12% and 200 ml according to the national institutes of health criteria; to be non- or ex-smoker of less than 10 pack-yr, to be neither pregnant nor breast-feeding and to be capable of completing asthma control test and spirometry. consecutive patients visiting the outpatient pulmonary department were included in the description.

Eligibility criteria:
inclusion criteria: 1. diagnosis of asthma, based on a history of episodic dyspnea and wheezing, and/or documented bronchodilator reversibility in forced expiratory volume in 1 s (fev1) of 12% and 200 ml according to the national institutes of health criteria; 2. to be non- or ex-smoker of less than 10 pack-yr, 3. to be neither pregnant nor breast-feeding 4. to be capable of completing asthma control test and spirometry. - exclusion criteria: any other pulmonary disorder than asthma. illiteracy. -

Keywords: asthma saba
functional icus in uganda and their survival outcomes

Conditions: Critical Illness

Summary: aim of the study is to describe the functional characteristics of icus in uganda and their @8-day patient characteristics it is a prospective cohort study .all icus in uganda will be included and their admitted patients followed upto 28 days in the icu for mortality

intensive care units are specialized units with expertise to provide organ support for the critically ill patients. there's a growing global burden of critical illness especially in the low-income coun-tries where critical care services are limited. despite advances in critical care, the mortality in uganda remains very high, with sepsis and trauma as the major contributors. there's paucity of literature regarding icus characteristics, disease burden and patient characteristics which could be contributing to the high mortality. objectives to describe the functional characteristics of the icus in uganda. to determine the icu mortality of critically ill patients in uganda. to determine the risk factors of mortality of patients admitted in the icu methods a prospective cohort study will be carried out in all icus in uganda. all new patients in the icus will be recruited into the study. data will be collected onto two separate questionnaires, one for patient characteristics and the second for icu functional characteristics. the patient's data will be collected within the first 24 hours and patients will be followed up for death\\discharge within 28 days in the icu. the data will be collected from the patients' charts and entered into epidata.

Eligibility criteria:
inclusion criteria: all new patients admitted to uganda's intensive care units icus in uganda whose unit heads verbally consent to participate in the study. exclusion criteria: patients transferred in from another unit will not be re recruited. icus that don't consent to the study.
understanding covid-19 infection in pregnant women and their babies

Conditions: Corona Virus Infection; Pregnancy Related; Neonatal Infection; Breastfeeding

Summary: this national study will recruit expectant mothers with and without positive nasopharyngeal swabs for sars-cov-2, and aims to determine the seroepidemiology of sars-cov-2 amongst expectant mothers and their infants in the u.k.


Eligibility criteria:
inclusion criteria: * signed informed consent form * any woman pregnant in selected hospitals in england who has no signs or symptoms of covid-19 disease during pregnancy and is rtpcr negative at delivery * any woman pregnant in any hospital in england who tests positive by rtpcr at any point during pregnancy from 24 weeks gestation onwards, regardless of signs and symptoms exclusion criteria: * if the pregnant woman is under 18 years in prison or unable to make an informed consent for other reasons (e.g. learning difficulties, language barriers)
efficacy and safety of a new oral rehydration solution (hipp ors 200 apple) in children with acute gastroenteritis

Conditions: Diarrhea

Summary: it is generally recommended that oral rehydration should be used as first-line therapy to treat or prevent dehydration in children with acute gastroenteritis (age). refusal to drink regular oral rehydration solution (ors) interfere with compliance with the recommended treatment. the objective of this study is to compare the tolerance, acceptance, efficacy and safety of a new ors (hipp ors 200 apple) of improved palatability with regular ors recommended by espghan in children with acute gastroenteritis (age).

it is generally recommended that oral rehydration should be used as first-line therapy to treat or prevent dehydration in children with acute gastroenteritis (age). despite the proven efficacy of oral rehydration therapy it remains underused. the main reason for this is that an ors neither reduces the frequency of bowel movements and fluid loss nor shortens the duration of illness, which decreases its acceptance. moreover, unpalatability of regular ors decrease its acceptance, especially in children with lower degrees of dehydration. refusal to drink regular ors interfere with compliance with the recommended treatment. parents, but also health care professionals, demand safe, effective, inexpensive, but also well tolerated and accepted ors for management of age. recently, a new ors (hipp ors 200 apple) with improved taste has been developed, and is now frequently employed for the management of age. the proposed study will be the first double-blind randomized trial of this ors. it will evaluate clinically meaningful benefits to be derived by children and caregivers from its use. if positive, this new ors may become a routine recommendation for children with age. the objective of this study is to compare the tolerance, acceptance, efficacy and safety of a new ors (hipp ors 200 apple) with regular ors recommended by espghan in children with age.

Eligibility criteria:
inclusion criteria: * children age 4 to 48 months * diarrhoea defined as the passage of three or more loose or watery stools per day for \>1 but \<5 days * mild (3%) or moderate dehydration (3-9%) according to the world health organization criteria (table 1) * informed consent signed by at least one parent / caregiver exclusion criteria: * diarrhea for \ 5 days * severe dehydration (\>9%) * recent history of diarrhea indicated either by parent/guardian or hospital case notes * underlying chronic gastrointestinal disease (i.e., celiac disease, cow's milk protein intolerance) * breastfeeding \>50% * under nutrition (weight/height ratio below the fifth percentile) * systemic infections * immune defects or immunosuppressive treatment

Keywords: diarrhea
pre and post orthopedic surgery sleep and cardiac testing (prospect)

Conditions: Obstructive Sleep Apnea

Summary: * evaluate sleep disordered breathing before and after orthopedic surgery utilizing a fda cleared to market (510k) home sleep study device (nexan inc., clearpath system) * compare berlin questionnaire and epworth sleep scale questionnaires to the home sleep study device results. * evaluate effectiveness of the home sleep study testing in the orthopedic presurgical population.


Eligibility criteria:
inclusion criteria: * undergoing knee or hip total joint replacement * answer yes to any prospect health history questions and/or score positive on the sleep questionnaires exclusion criteria: * tape allergy * previous diagnosis of obstructive sleep apnea

Keywords: perioperative obstructive sleep apnea screening home sleep testing
role of low dose epinephrine boluses in acute hypotension

Conditions: Hypotension and Shock

Summary: the study evaluates the role of low dose epinephrine boluses in management of acute hypo-tension vs the traditional management of acute hypo-tension. half of the participants suffering from acute hypo-tension will receive low dose epinephrine boluses (≤ 5 µg/kg/dose) and the other half will receive traditional management of shock

epinephrine, due to its alpha-1 and beta-adrenergic effects, is considered an important part of the management of children with hypo-tension. epinephrine is typically used as a continuous infusion (0.02-0.5 μg/kg/min) for severe sustained hypo-tension and as a bolus (0.01 mg/kg, maximum dose = 1 mg) for bradycardia, asystole, or pulse-less arrest. there are, however, clinical conditions that may benefit from smaller doses of bolus epinephrine. for example, brief periods of hypo-tension during medical procedures, intermittent hemodynamic instability, and augmentation of low blood pressure in a pre-arrest condition. while a resuscitation (or code) dose of epinephrine would be inappropriate (as it would cause an unacceptable large increase in blood pressure and heart rate \[hr\]), a smaller dose may be particularly useful. low-dose bolus vasopressors have been used for decades by anaesthesiologists to prevent post-re-perfusion injury after solid organ transplant, control cerebral oxygenation during anaesthesia and manage acute hypo-tension during spinal surgery. recently, use of bolus dose phenyl-ephrine has been described in the emergency department setting to augment blood pressure during periods of hypo-tension surrounding intubation. finally, free open access medical publications have provided some insight into using bolus dose pressors for acute hypotensive episodes in adults. however, there is few published data describing the use of low-dose vasopressor boluses in children.

Eligibility criteria:
inclusion criteria: * patients experiencing acute hypotensive episodes whether brief or during or after medical or surgical procedures exclusion criteria: * patients experiencing acute hypotensive episodes in arrest or pre-arrest situations